X
X

Bangalore KR Road

Home / Research & Trials / Bangalore KR Road

Bangalore – KR Road
Sl.No Principal Investigator’s Name Study Title Phase Protocol Number Indications Department Study Status Link Contact Person & Contact Details
1 Dr. Satheesh C T A Single-Arm, Phase 4 Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, in combination with Endocrine Therapy (Anastrozole/Letrozole or Fulvestrant) in Participants with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced and/or Metastatic Breast Cancer in India Phase 4 I3Y-IN-JPEC Breast Neoplasms, Neoplasm Metastasis Department of Medical Oncology Ongoing – Closed for Enrollment https://clinicaltrials.gov/ct2/show/NCT04707196 “Dr Geetha
Contact: 9980447199
E-Mail: [email protected]
2 Dr. Satheesh C T A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3) Phase 2b/3 CA-170-302 Non-Squamous Non-Small Cell Lung Cancers Department of Medical Oncology Ongoing http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=60435&EncHid=&userName=CA-170 “Dr Geetha
Contact: 9980447199
E-Mail: [email protected]
3 Dr. Raghunath S K “A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC)” Phase 3 BAY 1841788 / 21140 Hormone-sensitive prostate cancers Department of Uro-Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04736199 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
4 Dr. Satheesh C T A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) NonSmall Cell Lung Cancer (NSCLC). Phase 3 CR187-18 Lung Cancers Department of Medical Oncology Ongoing http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=61340 “Dr Sania Noor
Contact: 8088909754
E-Mail: [email protected]
5 Dr. Satheesh C T Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) Phase 3 D967UC00001 Metastatic Breast Cancers Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04784715 “Alina Ashraf
Contact: 9352984887
E-Mail: [email protected]
6 Dr. Satheesh C T An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) Phase 3 D967SC00001 Locally Advanced or Metastatic Non-Small Cell Lung Cancers Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT05048797 “Dr Geetha
Contact: 9980447199
E-Mail: [email protected]
7 Dr. Govind Babu A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patientreported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE). Phase 3 DP-1111-02CT Neuroendocrine Tumors Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04919226 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
8 Dr. Satheesh C T A Prospective, Multicentre, Post-Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HCC). Phase 4 E7080-M091-511 Hepatocellular Carcinomas Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04297254 “Dr Sania Noor
Contact: 8088909754
E-Mail: [email protected]
9 Dr. Govind Babu A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure MARIPOSA-2 Phase 3 61186372NSC3002 Carcinoma, Non-Small-Cell Lung Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04988295 “Alina Ashraf
Contact: 9352984887
E-Mail: [email protected]
10 Dr. Shekar Patil A Phase 4 Study of Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Renal CellCarcinoma and Intermediate- or Poor-risk Factors Conducted in India Phase 4 CA209-7C9 Advanced Kidney Cancers Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04513522 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
11 Dr. Satheesh C T A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) Phase 3 D361BC00001 Hormone-Sensitive Prostate Cancers Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04493853 “Dr Geetha
Contact: 9980447199
E-Mail: [email protected]
12 Dr. Satheesh C T A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) Phase 3 D910LC00001 Carcinoma, Non-Small-Cell Lung Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04385368 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
13 Dr. Satheesh C T A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2) Phase 3 D910MC00001 Carcinoma, Non- Small Cell Lung Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04642469 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
14 Dr. Srinivas BJ A randomized, multicenter, single dose, two-treatment, two-period, crossover, bioequivalence study of Mylan’s Paclitaxel Protein Bound Particles for Injectable Suspension (albumin-bound) and Abraxis BioScience’s Abraxane® for Injectable Suspension in 110 breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy (Bioequivalence Study) BA/BE PACL-1-19101 Breast Cancer Department of Medical Oncology Closed http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47568 “Dr Sania Noor
Contact: 8088909754
E-Mail: [email protected]
15 Dr. Satheesh C T Standard chemotherapy versus cancer stem cell assay directed chemotherapy in recurrent platinum resistant ovarian cancer. Phase 3 CG03-EOC Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT03949283 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
16 Dr. Govind Babu A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions Phase 2 42756493BLC2003 Urinary Bladder Neoplasms Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT04172675 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]
17 Dr. Govind Babu A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations Phase 2 42756493BLC2001 Urothelial Cancer Department of Medical Oncology Ongoing https://clinicaltrials.gov/ct2/show/NCT02365597 “Dr Apoorva Parameshwara
Contact: 8970269072
E-Mail: [email protected]

To get in touch with the Clinical Trials Team at HCG, please call on +91 80 4020 6000 (extn: 6058)

Research and Trials

To know more about facilities available for patients at HCG

HCG Call Icon